Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.
Sven M FrancqueAlexander HodgeJérôme BoursierZiad H YounesGerardo Rodriguez-AraujoGrace S ParkNaim AlkhouriManal F AbdelmalekPublished in: Hepatology communications (2024)
In this rollover study, CVC 150 mg once daily was well tolerated in patients with NASH and stage 0-4 liver fibrosis. No new safety signals were reported, and these data further support the safety and tolerability of CVC.